[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645365":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":33,"slug":7,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":54,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Geneplus-Beijing Co. Ltd.","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Fei Ma, MD","CONTACT","+8615010127581","drmafei@126.com",[15],{"facility":16,"status":7,"city":17,"state":7,"zip":18,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Beijing","100100","China","CN",{"type":22,"coordinates":23},"Point",[24,25],116.39723,39.9075,{"lat":25,"lon":24},[28,29],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":30,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100645365",false,"NCT07681323","Timing of ctDNA Testing in HR+\u002FHER2- Advanced Breast Cancer","Timing of ctDNA Testing in Advanced Breast Cancer: Impact on Prognosis and Treatment Strategies - A Prospective Observational Study (TIMING)","TIMING","Inclusion Criteria:\n\n* Histologically confirmed advanced breast cancer, molecular subtype HR+\u002FHER2-\n* Age ≥18 years\n* Expected survival \\>3 months\n* Willing to undergo ctDNA testing and sign informed consent form\n\nExclusion Criteria:\n\n* The subject has not signed the informed consent form.\n* Pregnant or breastfeeding women.\n* Other situations deemed by the investigator as unsuitable for inclusion in the study.","ALL","18 Years",{"count":43,"type":44},400,"ESTIMATED","OBSERVATIONAL","This multicenter, prospective observational cohort study aims to investigate the impact of ctDNA level and key actionable gene mutation status on prognosis and treatment response in patients with advanced HR+\u002FHER2- breast cancer.",[48],"Advanced Breast Cancer",[50,51,52,53],"ctDNA","multigene testing","HR+\u002FHER2- breast cancer","treatment strategy","NOT_YET_RECRUITING","2026-06-26",{"date":57,"type":58},"2026-07-02","ACTUAL",{"date":60,"type":44},"2026-06-30",{"date":62,"type":44},"2029-06-30",{"name":5,"class":6},1]